对药品包装标签的兼容性和安全性的评估
Chunwang Fu1, Fan Jiang1, Kun Gao1
1Shenyang Xingqi Pharmaceutical Co.,Ltd., Shenyang 110163, China.
Journal of pharmaceutical and biomedical analysis
|July 31, 2023
概括
在药品包装标签上发现了2,6-di-tert-butyl-4-methylphenol (BHT). 开发了一种经过验证的HPLC方法来定量BHT,随后进行毒理风险评估以确保药物安全.
科学领域:
- 制药科学 制药科学
- 分析化学 分析化学
- 毒理学 毒理学 毒理学
背景情况:
- 二次制药包装材料可以将化合物浸出到制药产品中.
- 确保药品质量需要分析包装中的可提取物和可浸出物.
研究的目的:
- 在药品包装标签上识别和量化2,6-di-tert-butyl-4-methylphenol (BHT).
- 开发和验证BHT的敏感分析方法.
- 评估与药品包装中的BHT相关的毒理风险.
主要方法:
- 使用高性能液态染色学 (HPLC),超高性能液态染色学-四极点飞行时间质谱学 (UPLC-Q-TOF-MS) 和核磁共振 (NMR) 光谱学识别化合物.
- 开发和验证一个敏感的HPLC方法用于BHT量化.
- 毒理风险评估. 毒理风险评估.
主要成果:
- 2,6-di-tert-butyl-4-methylphenol (BHT) 在药品包装标签上首次被发现.
- 成功开发并验证了一种有效而敏感的HPLC方法来定量BHT.
- 对BHT进行了全面的毒理风险评估.
结论:
- 药品包装标签中BHT的存在需要仔细监测.
- 开发的HPLC方法为量化BHT提供了可靠的工具.
- 毒理学评估确保使用这些包装材料的药物产品的安全.
相关概念视频
Drug Nomenclature
1.8K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.8K
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
230
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
230
Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
Factors Influencing Drug Absorption: Pharmaceutical Parameters
154
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
154
Pharmacovigilance
891
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
891


